Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).

1 finding from 1 review

Inhaled corticosteroids for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
RR 1.19 [1.09, 1.3]
2 studies · 1986 participants
Moderate

Medical or surgical intervention, or both, for gastro‐oesophageal reflux disease vs nil intervention, delayed intervention control, or placebo

Use of "rescue" medications and emergency action plans: B2 use puffs per day Duration of treatment: range 14 weeks to 24 weeks · treatment for asthma in adults and children with asthma and GORD

1 finding from 1 review

Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with… 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 239 participants
Moderate

Macrolides vs placebo

Use of rescue medication · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 314 participants
Low

Integrated disease management interventions vs usual care

Hospital days per patient, all causes · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Integrated disease management interventions for patients with chronic obstructive pulmonary disease 2021 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 3563 participants
Moderate

Breathing exercises vs inactive control

Days off work · adults with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Breathing exercises for adults with asthma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Myofunctional therapy vs sham

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 82 participants
Moderate

Myofunctional therapy vs CPAP + Myofunctional therapy

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Myofunctional therapy vs respiratory exercises + nasal dilator strip

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Myofunctional therapy vs medical treatment

Daytime sleepiness (ESS): change from baseline. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Myofunctional therapy vs waiting list control

Daytime sleepiness (ESS): change from baseline. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Myofunctional therapy vs continuous positive airway pressure (CPAP)

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Low

Mucolytic vs placebo

Days of disability per participant per month · chronic bronchitis or COPD

1 finding from 1 review

Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 2259 participants
Moderate

Effects of school‐based asthma interventions vs usual care

Experience of daytime and night‐time symptoms ‐ daytime symptoms (daytime symptoms) · children with asthma

1 finding from 1 review

School‐based self‐management interventions for asthma in children and adolescents: a mixed methods systematic review 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1065 participants
Moderate

Influenza vaccine vs placebo

Days disability from respiratory illness · COPD

The review found no eligible studies for this question.

1 finding from 1 review

Influenza vaccine for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antibiotics vs placebo or usual care

Symptom score at 10 days. Measured on a 7‐point scale (0 to 6) ; lower score denotes fewer symptoms · acute asthma exacerbation

1 finding from 1 review

Antibiotics for exacerbations of asthma 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2 participants
Moderate

Antibiotics vs placebo or usual care

Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation

Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).

1 finding from 1 review

Antibiotics for exacerbations of asthma 2018 · Cochrane Headline outcomes only
RD 0
3 studies · 502 participants
Low

Antibiotics vs placebo or usual care

Length of hospital stay · acute asthma exacerbation

1 finding from 1 review

Antibiotics for exacerbations of asthma 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low